Flavones as colorectal cancer chemopreventive agents - Phenol-O-methylation enhances efficacy

Cancer Prevention Research

Volumn 2, Issue 8, 2009, Pages 743-750

  Cai, Hong ^a   Sale, Stewart ^a   Schmid, Ralf ^b   Britton, Robert G ^a   Brown, Karen ^a   Steward, William P ^a   Gescher, Andreas J ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3',4',5',5,7 PENTAMETHOXYFLAVONE; APIGENIN; FLAVONE DERIVATIVE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; TRICIN; UNCLASSIFIED DRUG;

ADENOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CARCINOGENESIS; CELL PROLIFERATION; CHEMOPROPHYLAXIS; COLORECTAL CANCER; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DRUG EFFECT; DRUG EFFICACY; IC 50; IN VITRO STUDY; METHYLATION; MOLECULAR MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADENOMA; ANIMALS; ANTINEOPLASTIC AGENTS; APIGENIN; COLORECTAL NEOPLASMS; CYTOPROTECTION; DRUG EVALUATION, PRECLINICAL; FLAVONES; FLAVONOIDS; GENES, APC; HUMANS; METHYLATION; METHYLTRANSFERASES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, BIOLOGICAL; STRUCTURE-ACTIVITY RELATIONSHIP; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 70350014642     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0081     Document Type: Article

References (35)

1. Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci U S A 2001;98:10350-10355 (Pubitemid 32803023)
2. Deschner ES, Ruperto J, Wong G, Newmark HL. Quercetin and rutin as inhibitors of azoxymethanol-induced colonic neoplasia. Carcinogenesis 1991;12:1193-1196
3. Lamartiniere CA, Moore JB, Brown NM, et al. Genistein suppresses mammary cancer in rats. Carcinogenesis 1995;16:2833-2840
4. Min mice. Mol Cancer Ther 2005;4:1288-1292
5. Su LK, Kinzler KW, Vogelstein B, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1992;256:668-670
6. Gupta RA, DuBois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1:11-21. (Pubitemid 33741877)
7. Walle T, Ta N, Kawamori T, et al. Cancer chemopreventive properties of orally bioavailable flavonoids - methylated versus unmethylated flavones. Biochem Pharmacol 2007;73:1288-1296 (Pubitemid 46452585)
8. Patel D, Shukla S, Gupta S. Apigenin and cancer chemoprevention: progress, potential and promise. Int JOncol 2007;30:233-245
9. Kinoshita T, Firman K. Myrecetin, 5,7,3′,4′,5′- pentamethyl ether and other methylated flavonoids from Murraya paniculata. Phytochemistry 1997;45:179-181
10. Tomazela DM, Pupo MT, Passador AP, et al. Pyrano chalcones and a flavone from Neoraputia magnifica and their Trypanosoma cruzi glycosomal glyceraldehydes-3-phosphate dehydrogenase-inhibitory activities. Phytochemistry 2000;55:643-651
11. Choi CH, Kim JH, Kim SH. Reversal of P-glycoprotein-mediated MDR by 5,7,3′,4′,5′-pentamethoxyflavone and SAR. Biochem Biophys Res Commun 2004;320:672-679
12. De Giovanni C, Landuzzi L, Nicoletti G, et al. Apc10.1: an ApcMin/+ intestinal cell line with retention of heterozygosity. Int JCancer 2004;109:200-206 (Pubitemid 38240921)
13. Mateeva NN, Kode RN, Redda KK. Synthesis of novel flavonoid derivatives as potential HIV-integrase inhibitors. JHeterocyclic Chem 2002;39:1251-1258
14. Cai H, Brown K, Steward WP, Gescher AJ. Determination of 3′,4′,5′,5,7-pentamethoxyflavone in the plasma and intestinal mucosa of mice by HPLC with UV detection. Biomed Chromatogr 2009;23:335-339
15. Perkins S, Verschoyle RD, Hill K, et al. Chemopreventive efficacy and pharmacokinetics of curcumin in the Min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev 2002;11:535-540 (Pubitemid 34615160)
16. Workman P, Twentyman P, Balkwill F, et al. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br JCancer 1998;77:1-10.
17. Rao CV, Swamy MV, Patlolla JMR, Kopelovich L. Suppression of familial adenomatous polyposis by CP-31398, a TP53 modulator, in APC min/+ mice. Cancer Res 2008;68:7670-7675
18. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254
19. 2: the reason for low assay reliability. Prostaglandins 1980;19:933-945
20. Kurumbail RG, Stevens AM, Gierse JK, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996;384:644-648 (Pubitemid 27021518)
21. Selinsky BS, Gupta K, Sharkey CT, Loll PJ. Structural analysis of NSAID binding by prostaglandin H2 synthase: time-dependent and time-independent inhibitors elicit identical enzyme conformations. Biochemistry 2001;40:5172-5180 (Pubitemid 32373999)
22. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD. Improved protein-ligand docking using GOLD. Proteins 2003;52:609-623
23. Au A, Li BY, Wang WQ, et al. Effect of dietary apigenin on colonic ornithine decarboxylase activity, aberrant crypt foci formation, and tumorigenesis in different experimental models. Nutr Cancer 2006;54:243-251 (Pubitemid 44316307)
24. Min+ mouse and cyclooxygenase-2 in human-derived colon cancer cells. Int JCancer 2005;115:194-201.
25. Yamazaki R, Kusunoki N, Matsuzaki T, et al. Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett 2002;531:278-284 (Pubitemid 35341208)
26. Al-Fayez M, Cai H, Tunstall R, Steward WP, Gescher AJ. Differential modulation of cyclooxygenase-mediated prostaglandin production by the putative cancer chemopreventive flavonoids tricin, apigenin and quercetin. Cancer Chemother Pharmacol 2006;58:816-825 (Pubitemid 44351263)
27. Cai H, Boocock DJ, Steward WP, Gescher AJ. Tissue distribution in mice and metabolism in murine and human liver of apigenin and tricin, flavones with putative cancer chemopreventive properties. Cancer Chemother Pharmacol 2007;60:257-266 (Pubitemid 46742541)
28. Setchell KDR, Brown NM, Desai P, et al. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr 2001;131:1362-75S. (Pubitemid 32268489)
29. Tamvakopoulos C, Dimas K, Sofianos ZD, et al. Metabolism and anticancer activity of the curcumin analogue, dimethoxycurcumin. Clin Cancer Res 2007;13:1269-1277 (Pubitemid 46424068)
30. Min+/- (Min) mouse with R-flurbiprofen. Life Sci 2000;66:745-753
31. Boolbol SK, Dannenberg AJ, Chadburn A, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996;56:2556-2560 (Pubitemid 26171681)
32. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the Min mouse model of adenomatous polyposis. Cancer Res 2000;60:5040-5044
33. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenoma s with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-1316 (Pubitemid 23131373)
34. Steinbach G, Lynch PM, Phillips RKS, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl JMed 2000;342:1946-1952 (Pubitemid 30419089)
35. DeLano WL. The PyMOL molecular graphics system. San Carlos (CA): DeLano Scientific; 2002.